Verici Dx PLC
Company Profile
Business description
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Contact
19 Stanwell Road
Avon House
Penarth
CardiffCF64 2EZ
GBRT: +44 2920710570
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
stocks
Is the market still overlooking Alibaba’s AI potential?
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.10 | 63.00 | 0.69% |
| CAC 40 | 7,922.66 | 52.32 | 0.66% |
| DAX 40 | 24,367.62 | 9.88 | -0.04% |
| Dow JONES (US) | 44,930.05 | 18.79 | 0.04% |
| FTSE 100 | 9,144.70 | 32.54 | -0.35% |
| HKSE | 25,270.07 | 249.25 | -0.98% |
| NASDAQ | 21,619.94 | 90.73 | -0.42% |
| Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
| NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
| S&P 500 | 6,450.50 | 18.04 | -0.28% |
| S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
| SSE Composite Index | 3,696.77 | 30.33 | 0.83% |